Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin
about
FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaBA switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicityRepurposing the anti-malarial drug, quinacrine: new anti-colitis propertiesAcid ceramidase is upregulated in AML and represents a novel therapeutic target.Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia.10(-7) m 17β-oestradiol enhances odonto/osteogenic potency of human dental pulp stem cells by activation of the NF-κB pathwayTNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis.Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cellsApoptotic cell signaling in cancer progression and therapyVerticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3.Recent progress in targeting cancer.Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells.NF-κB pathway in colitis-associated cancersQuinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.Understanding the role of miRNA in regulating NF-κB in blood cancer.Apoptosis and molecular targeting therapy in cancer.Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells.Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.Trefoil factor family 2 expression inhibits gastric cancer cell growth and invasion in vitro via interactions with the transcription factor Sp3.Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.Poor antibody validation is a challenge in biomedical research: a case study for detection of c-FLIP.Adamantyl arotinoids that inhibit IκB kinase α and IκB kinase β.Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of BaxAmsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1.TRADD is critical for resistance to TRAIL-induced cell death through NF-κB activation.Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity.Quantifying nuclear p65 as a parameter for NF-κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot.Hedgehog signaling drives cellular survival in human colon carcinoma cells.Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP).Quinacrine Inhibits ICAM-1 Transcription by Blocking DNA Binding of the NF-κB Subunit p65 and Sensitizes Human Lung Adenocarcinoma A549 Cells to TNF-α and the Fas Ligand.TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions.
P2860
Q24300387-5A8119EA-1BC6-48A1-98A9-81E9F91C3889Q28477095-D0639063-E99A-4DD3-9E19-2ED75F1E7FBBQ28817699-5D3F454D-DD6F-4E3C-9B6F-BFEFC68060A1Q30275460-F04F5B01-A7BB-4779-A910-1B5859CBF395Q30409637-D2F9B1B1-0B92-4449-B75B-F809A9302A72Q33785449-488D528E-40E7-45AE-8D8F-DD2F947312A9Q33802588-99E1AD2E-2247-438B-9B9B-1EFD76DAF8BEQ34000612-E2DD1A91-43FD-46A8-B645-62864E4A0F40Q34060669-EE6783FD-F089-49EE-B283-F0A28ED88112Q35088734-B161809C-FFE4-4EB1-A260-B7B61C0C54BEQ35501202-4DA06FFF-0130-43A2-920F-79B922F7A2E6Q35740782-6239704D-393F-434A-B26F-14FA6D20DE91Q35762274-C16271F0-E485-4F5E-B2E2-A50950AC8427Q36431068-12051A42-9C51-4523-9914-A9C348498282Q36795773-AC468B9E-1544-451C-A885-3B15B6E0473AQ37702210-BB3B871C-E713-487B-AD28-9D10486D2B08Q37972140-C9B3C536-EF0F-41A8-A7ED-BA1C7B03F56BQ38228349-B8D7715B-8809-4960-B2A0-431530CA4572Q38281336-C702C577-882C-4CC8-A086-28A4FA089F70Q38681598-2E553533-C423-4898-B363-070679DF607EQ38743770-0F29DECE-2E7C-4B21-8D7F-5E0C75555480Q38777239-E66705C7-1394-4B90-9277-7E1AA5158E01Q39114961-3B36F994-837F-49A4-B833-1120FBAE0F33Q39154856-130DA1FF-125E-49E0-A90F-4DDFE32CDBB0Q39205142-0427B03F-4F6F-4803-9DBC-A77CD537F4FCQ39273277-C8C35A11-8DD7-49D3-8475-241184D12B25Q39533119-A3B10364-C5F1-471B-B1AD-6A179653E161Q39547659-58EBCAB1-7D42-4820-8565-78F8BD8CCCE8Q39552773-017223B8-1EDE-4537-8E08-9F2CC84152B9Q39623310-3E0AA0DA-F5E4-4230-959B-C820A8476641Q47874310-21FAE161-91CE-4EE2-8863-8B8A5ACB3951Q48174470-BB9D24F8-DF5E-4DEA-BB36-38824245AA2BQ52495885-FB82EC1A-D001-44FE-B779-38B9BF684B38
P2860
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Inhibition of NF-kappaB signal ...... ligand (TRAIL) or oxaliplatin
@en
Inhibition of NF-kappaB signal ...... ated apoptosis-inducing ligand
@nl
type
label
Inhibition of NF-kappaB signal ...... ligand (TRAIL) or oxaliplatin
@en
Inhibition of NF-kappaB signal ...... ated apoptosis-inducing ligand
@nl
prefLabel
Inhibition of NF-kappaB signal ...... ligand (TRAIL) or oxaliplatin
@en
Inhibition of NF-kappaB signal ...... ated apoptosis-inducing ligand
@nl
P2093
P2860
P356
P1476
Inhibition of NF-kappaB signal ...... ligand (TRAIL) or oxaliplatin
@en
P2093
Akwasi Agyeman
Janet A Houghton
Jennifer DeVecchio
Tanvi S Jani
Tapati Mazumdar
P2860
P304
19162-19172
P356
10.1074/JBC.M109.091645
P407
P577
2010-04-27T00:00:00Z